Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

l minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay of the webcast will be archived on the Sunesis website for two weeks until March 25, 2008.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of product candidates in oncology focused on inhibition of the cell-cycle and survival signaling. Our lead product candidate, SNS-595, is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double-strand DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 combination with cytarabine in relapsed/refractory AML are both ongoing. SNS-032, a potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other protein kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information o
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... York , September 23, 2014 ... leading provider of  Closed System Transfer     Devices ... exclusive partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s ... in Taiwan , ... as the company continues to expand globally, and ...
(Date:9/23/2014)... 23, 2014 Dr. Williams says, “Find ... on healthcare offers a three phase process that can ... delivery system that would go far beyond anything previously ... the delivery of healthcare.” , “Every effort to improve ... to provide discernable progress throughout that system because all ...
(Date:9/23/2014)... England , September 23, 2014 ... launched with funding from Imperial Innovations, Cambridge Innovation Capital ... Inivata, a clinical cancer genomics company focused on ... analysis to improve cancer testing and treatment, today ... round led by Imperial Innovations and including Cambridge ...
(Date:9/22/2014)... and SANTA CLARA, Calif. , Sept. ... WBMD ), the leading source of health information, ... survey that provide novel insights regarding physician and ... and care.  Dr. Eric Topol , a leading ... who serves as both Editor-in-Chief of Medscape and Chief ...
Breaking Biology Technology:Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4
... Bowl MVP,s; 94 NFL First Round Draft Picks; ... ... BASKING RIDGE, N.J., Feb. 8 Millennium,Biotechnologies Inc., wholly-owned subsidiary ... SURGEX(TM) is,currently being administered as the exclusive post workout nutritional,product provided ...
... Calif., Feb. 8 Genomic Health,Inc. (Nasdaq: GHDX ... Chief Operations Officer, will present at the BIO CEO ... 2008 at 10:15 a.m. Eastern,Time., To access the ... Investor Relations section of Genomic Health,s,website at http://investor.genomichealth.com ...
... available in Spanish . , ANN ARBOR, ... from walking to operate a portable GPS locator, a ... neurotransmitter, research involving the University of Michigan shows. , ... Feb. 8 issue of the journal Science. Authors include ...
Cached Biology Technology:Tom Shaw's NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen 2Tom Shaw's NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen 3Knee brace generates electricity from walking 2
(Date:9/23/2014)... Rice University scientists who are fighting a cyberwar against ... clinician,s most powerful ally. , "Recent research has found ... the immune system, and we studied the interplay between ... might turn the tables on cancer," said Rice University,s ... in the Early Edition of the Proceedings of ...
(Date:9/23/2014)... the washing up, negotiating rights to the TV remote control ... university for the new academic year are about to learn ... business. , And now research from academics at The University ... to monitor their energy usage in the home could be ... a team of technology experts and psychologists found that meters ...
(Date:9/23/2014)... 2014 Research and Markets  has announced ... and Opportunities, 2019" report to their offering. ... enhancing security and protection in private as well as ... country,s government is focusing on using biometric systems to ... national IDs that are of crucial importance to the ...
Breaking Biology News(10 mins):Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3Smart meters could cause conflict for housemates, study shows 2Smart meters could cause conflict for housemates, study shows 3India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3
... Military, homeland security, law enforcement and other first-responder ... to attend the 2009 Force Protection Equipment Demonstration ... 600 exhibits will be presented at Stafford County ... Quantico, VA. Live-fire small arms and explosives survivability ...
... Technology (Caltech) and the University of California at San ... Caltech experimental data to show just how amino-acid chains ... Their insights were recently published in the February 10 ... of Sciences (PNAS). The paper details the ...
... human genome eight years ago, enormous progress has been ... of most human genes is still barely understood. An ... gene or protein is to compare its sequence with ... experimentally easier to investigate. From the functions of related ...
Cached Biology News:Demonstration Targets Terrorism 2Caltech and UCSD researchers shed light on how proteins find their shapes 2Relationships in rank and file 2Relationships in rank and file 3Relationships in rank and file 4
... service provides the premium quality siRNAs you ... siRNAs can be readily ordered online by ... or by providing the sense and antisense ... Silencer Validated and Silencer ...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and ...
dithiothreitol, sulfhydryl reducing agent, C4H10O2S2; MW: 154.24, 97% pure (minimum), CAS No: 27565-41-9, store at -20 C ...
... NAP-10 Columns, 50. For rapid and ... 10-mers) in less than 15 minutes by ... in distilled water containing 0.15% Kathon CG/ICP ... volume: 0.5 ml (NAP-5), 1 ml ...
Biology Products: